Eli Lilly secures conditional marketing authorisation for olaratumab injection with doxorubicin

The European Commission (EC) has granted conditional marketing authorisation for Eli Lilly and Company ’s (LLY) olaratumab injection of 10mg/ml in combination with doxorubicin, to treat adults with advanced soft tissue sarcoma (STS) who are not suited…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news